Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2186

Sort by

Sort Order Select

Journal Articles

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

Erwan Dumontet, Céline Pangault, David Roulois, Matthis Desoteux, Simon Léonard, Tony Marchand, Maelle Latour, Patricia Legoix, Damarys Loew, Florent Dingli, Joelle Dulong, Erwan Flecher, Cédric Coulouarn, Guillaume Cartron, Thierry Fest, Karin Tarte

Blood (2021) 138 (1): 57–70.

https://doi.org/10.1182/blood.2020008791

Published: 2021

Includes: Supplemental data

Journal Articles

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors

Blood (2021) 137 (18): 2481–2494.

https://doi.org/10.1182/blood.2020005627

Published: 2021

Includes: Supplemental data

Journal Articles

Occupy BTK: the key to controlling CLL

Philip A. Thompson

Blood (2020) 136 (1): 4–6.

https://doi.org/10.1182/blood.2020005877

Published: 2020

Journal Articles

Increased mTOR activation in idiopathic multicentric Castleman disease

Daniel J. Arenas, Katherine Floess, Dale Kobrin, Ruth-Anne Langan Pai, Maya B. Srkalovic, Mark-Avery Tamakloe, Rozena Rasheed, Jasira Ziglar, Johnson Khor, Sophia A. T. Parente, Sheila K. Pierson, Daniel Martinez, Gerald B. Wertheim, Taku Kambayashi, Joseph Baur, David T. Teachey, David C. Fajgenbaum

Blood (2020) 135 (19): 1673–1684.

https://doi.org/10.1182/blood.2019002792

Published: 2020

Includes: Supplemental data

Journal Articles

Overview of Castleman disease

Angela Dispenzieri, David C. Fajgenbaum

Blood (2020) 135 (16): 1353–1364.

https://doi.org/10.1182/blood.2019000931

Published: 2020

Journal Articles

Unexpected lymph node finding in a patient with essential thrombocythemia

Daniel A. Hale, John R. Krause

Blood (2020) 135 (2): 154.

https://doi.org/10.1182/blood.2019002036

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

CD4 + T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism

Matteo Bellone, MD, Paolo Dellabona, MD PhD, Arianna Calcinotto, BS, Giulia Casorati, PhD, Alessandra Rovida, PhD, Maria Teresa Sabrina Bertilaccio, PhD, Elena Cattaneo, Matteo Grioni, Federico caligaris-Cappio, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 683.

https://doi.org/10.1182/blood-2019-128246

Published: 2019

Journal Articles

Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment

Joseph G Taylor, MBBS, BSc, Andrew James Clear, BSc, Edward Truelove, MBBS, BSc, MRCP, FRCPath, Mariarita Calaminici, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 658.

https://doi.org/10.1182/blood-2019-125247

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Y. Lynn Lynn Wang, MD PhD, Carrie Franzen, PhD, Shengchun Wang, MD PhD, Girish Venkataraman, MD MBBS, Lei Li, MS, Nifang Niu, PhD, Madina Sukhanova, PhD, Yifan Tu, MD PhD, Juehua Gao, MD PhD, Yi-Hua Chen, MD, Shuo Ma, MD PhD, Richard A. Larson, MD, Lu Pin, MD PhD

Blood (2019) 134 (Supplement_1): 475.

https://doi.org/10.1182/blood-2019-125396

Published: 2019

Journal Articles

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Zhenghao Chen, Gaspard Cretenet, Hanneke ter Burg, Gabriela Andrejeva, Jeffrey C Rathmell, Francesco Forconi, MD DM, PhD FRCPath, Gerritje J. W. van der Windt, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 479.

https://doi.org/10.1182/blood-2019-123005

Published: 2019

Journal Articles

Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 547.

https://doi.org/10.1182/blood-2019-121584

Published: 2019

Journal Articles

Single-Cell RNA Sequencing Identifies a Pseudo-Immune Differentiation Axis As the Main Source of Functional Heterogeneity in Follicular Lymphoma B-Cells

Noudjoud Attaf, Inaki Cervera-Marzal, Laurine Gil, Chuang Dong, Jean-Marc Navarro, PhD, Lionel Spinelli, PhD, Bertrand Nadel, PhD, Pierre Milpied, PhD

Blood (2019) 134 (Supplement_1): 548.

https://doi.org/10.1182/blood-2019-125718

Published: 2019

Journal Articles

Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd

Joshua D Brandstadter, MD PhD, Eric Perkey, Brian T. Gaudette, PhD, Léolène Carrington, PhD, Daniela Gomez-Atria, PhD, Bruce R. Blazar, MD, Burkhard Ludewig, PhD, Anastasia Tikhonova, PhD, Iannis Aifantis, PhD, David Allman, PhD, Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): 588.

https://doi.org/10.1182/blood-2019-123533

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Single Cell Immune Profiling of Colitogenic T Cells during Acute Graft Versus Host Disease Reveals Two Novel Transcriptionally Distinct CD4+ GM-CSF+ Lineages

Clinton Piper, BS, Achia Khatun, BS, Yao Chen, BS, Ryan Zander, PhD, Weiguo Cui, MD PhD, William R. Drobyski, MD

Blood (2019) 134 (Supplement_1): 197.

https://doi.org/10.1182/blood-2019-127095

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

NARROW

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors

Occupy BTK: the key to controlling CLL

Increased mTOR activation in idiopathic multicentric Castleman disease

Overview of Castleman disease

Unexpected lymph node finding in a patient with essential thrombocythemia

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

CD4 + T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism

Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

Single-Cell RNA Sequencing Identifies a Pseudo-Immune Differentiation Axis As the Main Source of Functional Heterogeneity in Follicular Lymphoma B-Cells

Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Single Cell Immune Profiling of Colitogenic T Cells during Acute Graft Versus Host Disease Reveals Two Novel Transcriptionally Distinct CD4+ GM-CSF+ Lineages

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only